Swedish startup Aligned Bio is advancing a nanowire-based approach to convert sequencing-by-synthesis (SBS) instruments into single-molecule sequencers. The company presented proof-of-concept data at the European Society of Human Genetics (ESHG) annual meeting, reporting demonstration using an Illumina MiSeq while pursuing the sensitivity gains expected from nanowire detection. Aligned Bio says its strategy leverages nanowire arrays for higher-sensitivity signal capture, potentially reducing the need for cluster amplification that traditional SBS workflows use to boost base-incorporation reads. The company also pivoted away from building a full custom sequencer, citing financial feasibility and instead targeting retrofits or integration with existing SBS platforms. While commercialization timelines were not provided, the technical direction points to efforts to preserve the operational familiarity of current sequencing ecosystems while changing the detection layer for single-molecule performance.